Compare VIVS & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIVS | ALBT |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.3M |
| IPO Year | N/A | 2015 |
| Metric | VIVS | ALBT |
|---|---|---|
| Price | $1.16 | $0.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.6K | ★ 349.1K |
| Earning Date | 06-04-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.38 | N/A |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $0.21 |
| 52 Week High | $5.30 | $4.74 |
| Indicator | VIVS | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 36.25 | 45.27 |
| Support Level | $1.13 | $0.34 |
| Resistance Level | $1.38 | $0.41 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 11.36 | 50.56 |
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.